Related Experiment Videos
PML/RAR alpha(+) hypergranular acute promyelocytic leukemia (M3) developing into an M3 acute myelocytic leukemia
G J Ruiz-Argüelles1, G J Ruiz-Delgado, V Reyes-Núñez
1Centro de Hematología y Medicina Interna de Puebla, Universidad La Salle, México, México. gruiz1@prodigy.net.mx
Abstract:
The case of an adult with PML/RARalpha(+) hypergranular acute promyelocytic leukemia (M3) that evolved into a rapidly fatal M3 acute myelocytic leukemia without PML/RARalpha after a complete and molecular remission had been achieved, is presented. Only 7 such cases have been published in the literature. The possible origin of this either leukemic relapse or secondary malignancy is briefly discussed, focusing on the fact that this diagnosis could only be defined by adequate molecular biology studies in the leukemic cells.
Insights
A rare case of acute promyelocytic leukemia (M3) relapsing without the PML/RARalpha fusion gene is presented. This evolution highlights the need for molecular studies to distinguish relapse from secondary leukemia.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Acute promyelocytic leukemia (APL), or M3, is characterized by the PML/RARalpha fusion gene.
- Treatment can achieve complete and molecular remission.
Observation:
- A rare case of an adult with APL (M3) is presented.
- The leukemia evolved into M3 acute myelocytic leukemia lacking the PML/RARalpha fusion gene after remission.
Findings:
- This evolution represents either a leukemic relapse or a secondary malignancy.
- Only 7 similar cases have been documented in medical literature.
Implications:
- Accurate diagnosis requires molecular biology studies of leukemic cells.
- Understanding such rare evolutions is crucial for APL patient management.